David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FISCAL THIRD QUARTER 2014

CRYO-CELL REPORTS FISCAL THIRD QUARTER 2014 RESULTS

OLDSMAR, Fla. October 15, 2014 Cryo-Cell International, Inc. (the Company ) (OTC:QB Markets Group Symbol:

CCEL), the world s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2014.

Consolidated revenues for the third quarter of fiscal 2014 were approximately $4.9 million compared to approximately $4.8 million for the third

quarter of fiscal 2013. The revenues for the third quarter of fiscal 2014 consisted of approximately $4.8 million in processing and storage fee revenue and approximately $169,000 in licensee income, compared to approximately $4.5 million in

processing and storage fee revenue and approximately $324,000 in licensee income for the third quarter of fiscal 2013. The 48% decrease in licensee income for the three months ended August 31, 2014 compared to the three months ended

August 31, 2013 is the result of decreased licensee income from Cryo-Cell de Mexico ( Mexico ) as Mexico paid the remaining balance due under the amendment to the license agreement during the first fiscal quarter of 2014. There will

be no further licensee income recognized pursuant to that agreement. The remaining licensee income (and all of the licensee income for the three months ended August 31, 2013) consists of royalty income earned on the processing and storage of

cord blood stem cell specimens in geographic areas where the Company has license agreements.

The Company reported net income for the three months ended August 31, 2014 of approximately $237,000, or $0.02 per basic and diluted

share, compared to net income of approximately $194,000, or $0.02 per basic and diluted share for the three months ended August 31, 2013. The increase in net income for the three months ended August 31, 2014 is partially a result of a 2%

increase in revenues and a settlement received from litigation. This was offset by a 4% increase in selling, general and administrative expenses and a 10% increase in cost of sales. The increase in cost of sales is a result of the increase in

laboratory costs associated with the processing technology the Company began using during the fourth quarter of fiscal 2013.

At August 31, 2014, the Company had cash and cash equivalents of $3,448,977. The Company s cash

decreased by approximately $476,000 during the first nine months of fiscal 2014, primarily as a result of approximately $2,295,000 used for the stock repurchase plan pursuant to which the Company repurchased 968,302 shares of the Company s

common stock during the nine months ended August 31, 2014 which was offset by approximately $1,312,000 by cash provided by operations and the release of approximately $764,000 of previously restricted cash in a trust. As of August 31,

2014, the Company had no long-term indebtedness.

About Cryo-Cell International, Inc.

Founded in 1989, Cryo-Cell International, Inc. is the world s first private cord blood bank. More than 500,000 parents from 87 countries

trust Cryo-Cell to preserve their family members stem cells. Cryo-Cell s mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a

facility that is FDA registered, cGMP-/cGTP-compliant and is licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell is also the first U.S. (for private use only) cord blood bank to receive FACT

accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Cryo-Cell is ISO 9001:2008 certified by BSI, an internationally recognized,

quality assessment organization. Cryo-Cell is a publicly traded company, OTCQB:CCEL. For more information, please visit www.cryo-cell.com.

Forward-Looking Statement

wherein the terms believes , intends , projects , anticipates , expects , and similar expressions as used are intended to reflect forward-looking statements of the Company. The

information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside

the control of the Company. These uncertainties and other factors include the success of the Company s global expansion initiatives and product diversification, the Company s actual future ownership stake in future therapies emerging from

its collaborative research partnerships, the success related to its IP portfolio, the Company s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on

the Company s business, the Company s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the

Company s menstrual stem cell technology license agreements and umbilical cord blood license agreements and their ability to provide the Company with royalty fees, the ability of the reproductive tissue storage to generate new revenues for the

Company and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on

Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.